Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 20:04:38时区推断·⟳ 抓取 20:08:26·⚡ 决策 08-04 22:28:56 +2h20m·83.9 天前
AbbVie旗下Allergan Aesthetics的Botox Cosmetic咬肌突出适应症补充BLA获FDA受理审评
本次是FDA受理审评而非批准上市，短线确定性弱于正式获批。
📄 原文Investing.com↗ 原文
Allergan submits Botox application for jawline treatment
BofA says this memory stock could double. Here are 5 reasons why IRVINE, Calif. - AbbVie (NYSE:ABBV) announced today th…
不做 AbbVie（ABBV.US）
当前只是FDA受理补充BLA而非获批，且MMP全球申报计划此前已公开；相对AbbVie收入和市值缺乏可量化短线增量，不做。
不做 Evolus（EOLS.US）
竞争压力仅来自未来潜在标签获批，当前AbbVie只是进入审评阶段，尚不足以构成明确强空催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Investing.com按公司新闻稿口径报道FDA已受理Botox Cosmetic用于成人咬肌突出美容适应症的补充BLA。
- AbbVie此前已披露Botox Cosmetic在中国获批用于MMP，并计划在更多全球市场推进监管申报，削弱今日美国受理的意外性。
关键理由
- 本次是FDA受理审评而非批准上市，短线确定性弱于正式获批。
- Botox Cosmetic 2025年全球收入约26.02亿美元，占AbbVie 2025年611.6亿美元收入约4.3%；咬肌突出若未来获批只是其中一个新增美容适应症，当前受理节点无法量化新增收入。
- 该适应症已于2024年在中国获批并披露后续全球申报计划，今日美国受理属于管线推进而非完全意外的商业化落地。
主要风险
- 若FDA最终批准且给出明确PDUFA或商业化指引，AbbVie在美国医美毒素市场的先发标签优势需要重新评估。
- 近期AbbVie的交易主线仍是Q2业绩、免疫产品增长和Apogee收购影响，单一美容适应症受理容易被主线淹没。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-31 · 影响 weakens
近期Q2报道显示AbbVie主线为免疫产品增长、Apogee收购压低全年EPS指引及医美业务表现平淡，削弱单一适应症受理的短线主导性。
检索:AbbVie 2026 Q2 aesthetics revenue flat Apogee lowered guidance Botox Cosmetic 原文 ↗ - 做多前查反向 · 来源 web · 日期 2024-09-11 · 影响 weakens
公司早在中国MMP获批时已公开表示会推进额外全球监管申请，今日美国受理的预期差有限。
检索:Botox Cosmetic masseter muscle prominence China approval additional regulatory applications planned globally 2024 原文 ↗
原文全文
展开原文 · 2,093 字
BofA says this memory stock could double. Here are 5 reasons why
IRVINE, Calif. - AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration has accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence in adults.
The submission seeks approval for the temporary improvement in the appearance of marked to very marked masseter muscle prominence associated with masseter muscle activity. If approved, Botox Cosmetic would be the first neurotoxin indicated for this condition in the U.S. and would represent the product’s fifth aesthetic indication.
The application is supported by two Phase 3 clinical studies, M21-416 and M21-417, which met their primary endpoints. Both studies demonstrated statistically significant improvements in the severity of masseter muscle prominence compared with placebo. The safety profile was consistent with established uses, with no new safety signals identified, according to a press release statement.
Patient satisfaction data showed that twice as many patients treated with Botox Cosmetic reported being "Very Satisfied" or "Satisfied" compared with placebo.
Masseter muscle prominence can contribute to the appearance of a wider or more square lower face. The treatment addresses patient interest in non-surgical facial contouring options for jawline definition and shape.
Botox Cosmetic is currently indicated in adult patients for the temporary improvement in the appearance of moderate to severe glabellar lines, lateral canthal lines, forehead lines, and platysma bands.
The product carries a boxed warning regarding the distant spread of toxin effect. Postmarketing reports indicate that effects may spread from the injection area to produce symptoms including muscle weakness, swallowing difficulties, and breathing difficulties, which can be life threatening.
The information is based on a press release statement from Allergan Aesthetics, an AbbVie company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
IRVINE, Calif. - AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration has accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence in adults.
The submission seeks approval for the temporary improvement in the appearance of marked to very marked masseter muscle prominence associated with masseter muscle activity. If approved, Botox Cosmetic would be the first neurotoxin indicated for this condition in the U.S. and would represent the product’s fifth aesthetic indication.
The application is supported by two Phase 3 clinical studies, M21-416 and M21-417, which met their primary endpoints. Both studies demonstrated statistically significant improvements in the severity of masseter muscle prominence compared with placebo. The safety profile was consistent with established uses, with no new safety signals identified, according to a press release statement.
Patient satisfaction data showed that twice as many patients treated with Botox Cosmetic reported being "Very Satisfied" or "Satisfied" compared with placebo.
Masseter muscle prominence can contribute to the appearance of a wider or more square lower face. The treatment addresses patient interest in non-surgical facial contouring options for jawline definition and shape.
Botox Cosmetic is currently indicated in adult patients for the temporary improvement in the appearance of moderate to severe glabellar lines, lateral canthal lines, forehead lines, and platysma bands.
The product carries a boxed warning regarding the distant spread of toxin effect. Postmarketing reports indicate that effects may spread from the injection area to produce symptoms including muscle weakness, swallowing difficulties, and breathing difficulties, which can be life threatening.
The information is based on a press release statement from Allergan Aesthetics, an AbbVie company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。